CClinicalTrials.gg
CompletedNCT05222217Updated Feb 3, 2022

Gatekeeper for Soiling and Gas Incontinence

An observational study in Gas Incontinence and Soilings, Fecal, sponsored by Hospital Mutua de Terrassa. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-03.

Sponsored by Hospital Mutua de Terrassa · Observational

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
13
Ages
18 Years and older
Sex
All
01

Study summary

Faecal incontinence has a broad spectrum of symptoms. Some patients only suffer commonly considered mild symptoms: gas incontinence and soiling, but patients' quality of life is significantly impaired. Although several treatments for faecal incontinence are available, this subgroup of patients are difficult to treat, and no therapeutic alternative has been clearly defined.

The aim of this study is to evaluate Gatekeeper™ treatment for this subgroup of patients with faecal incontinence, not studied before.

Consecutive case series single-centre study. Patients with mainly soiling and/or gas incontinence were treated with polyacrylonitrile prostheses

02

Conditions studied

  • Gas Incontinence
  • Soilings, Fecal

Browse trials for

03

In context

Fecal Incontinence

312 studies on the registry are indexed under Fecal Incontinence; 57 are open to participants now.

This study's enrollment of 13 is below the median of 100 across 79 observational studies indexed under Fecal Incontinence.

Browse Fecal Incontinence studies →

Lead sponsor

Hospital Mutua de Terrassa is the lead sponsor of 33 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients' selection was based on clinical history, physical examination, preoperative 3D-endoanal ultrasound (EUS) and a continence diary recorded for 21 days. Patients with previous history of chronic diarrhoea were evaluated by the gastroenterology team and if needed, fibre supplementation or other medical treatment was used to obtain a Bristol score of 3-4 before entering the study

Inclusion criteria

  • patients older than 18 years old
  • with at least 6 months of GI and/or soiling
  • non-responding to conservative treatment and biofeedback.

Exclusion criteria

Exclusion Criteria:

  • complete solid and liquid FI
  • common Bristol score > 4
  • malignant diseases
  • chronic diarrhoea
  • inflammatory bowel disease
  • acute anorectal disease
  • rectal prolapse
  • neurological disease,
  • obstructive defecation syndrome
  • low anterior resection syndrome,
  • previous pelvic radiation,
  • any anaesthetic contraindication
  • St. Mark's score > 12
  • external anal sphincter lesion > 30º.
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
13 participants (actual)
Patient registry
No

Interventions

  • DeviceGatekeeper

    Six polyacrylonitrile prostheses (THD Gatekeeper™ Delivery System, THD SpA, Correggio, Italy) were implanted under 3D-EUS control through a 5mm perianal incision at 1, 3, 5, 7, 9 and 11 o'clock in lithotomy position, and located in the upper-middle intersphincteric space of the anal canal, using a specifically designed system.

06

What researchers measure

Primary outcomes

  1. Change in the number of gas incontinence and soiling episodes

    Each patient completes a three-week continence diary specifically recording gas incontinence and soiling episodes at baseline and before every follow-up visit.

    Time frame: 6, 12 and 24 months after surgery

  2. Changes in incontinence symptoms

    Evaluation of incontinence symptoms with the St. Mark's Incontinence Score. Score from 0 to 24, where 0 means "complete continence" and 24 means "severe fecal incontinence"

    Time frame: 6, 12 and 24 months after surgery

  3. Patient's Subjective Perception

    Changes in patient subjective evaluation using a Visual Analogue Scale (VAS). Score from 0 to 10, where 0 means "no problem" and 10 means "severe problem and alteration of my quality of life"

    Time frame: 6, 12 and 24 months after surgery

Secondary outcomes

  1. Changes in prostheses location

    Prostheses migration was defined as displacement of the prosthesis to the suprasphincteric space detected during the follow-up, detected with 3D-Endoanal Ultrasound.

    Time frame: baseline and one month after surgery

  2. Differences in anal pressures

    Measurement of differences in anal testing pressures using a four-channel manometer

    Time frame: baseline and three months after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05222217
Lead sponsor
Hospital Mutua de Terrassa
Responsible party
Arantxa Muñoz-Duyos (Clinical Chief of General and Digestive Surgery, Hospital Mutua de Terrassa) — Principal investigator
First posted
Feb 3, 2022
Start date
Jan 2014
Primary completion
Nov 2015
Completion
Dec 2015
Last update
Feb 3, 2022

Oversight

FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion